TScan Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for TScan Therapeutics, Inc. (TCRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-127.50-89.22-66.22-48.63-26.13
Depreciation & Amortization4.115.365.143.331.23
Stock Based Compensation9.555.214.552.520.52
Change in Working Capital5.0517.61-8.18-5.9021.36
Change in Accounts Payable1.99-0.050.530.011.13
Change in Other Working Capital5.885.77-1.730.630.79
Other Operating Activities1.860.762.762.510.00
Net Cash from Operating Activities-110.82-61.36-66.50-48.68-3.02
Investing Activities
Capital Expenditures-3.83-3.154.23-9.94-4.24
Purchases of Investments-48.79-57.610.000.000.00
Sales/Maturities of Investments192.66-57.610.000.000.00
Net Cash from Investing Activities-52.61-60.76-4.23-9.94-4.24
Financing Activities
Debt Repayment15.310.00-0.320.000.00
Common Stock Issued35.1843.130.1989.650.29
Other Financing Activities158.2792.32-0.320.000.00
Net Cash from Financing Activities208.77135.4429.36189.670.29
Summary
Net Change in Cash45.3313.33-41.37131.05-6.97
Cash at Beginning of Period138.39125.06166.4435.390.00
Cash at End of Period183.7213.33125.06166.440.00
Free Cash Flow-114.65-64.50-70.73-58.62-7.26
Supplemental Disclosures
Interest Paid2.883.000.660.000.00